Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

NCT01499355
terminatedphase_2

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

NCT01930890
completedphase_1

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

NCT01943513
completedphase_1

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

NCT00771329

Clinical Trials (4)

Showing 4 of 4 trials
NCT01499355Phase 2

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Terminated
NCT01930890Phase 2

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Terminated
NCT01943513Phase 1

A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers

Completed
NCT00771329Phase 1

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4